These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 27215392)

  • 1. Advanced therapies in Parkinson's disease: Long-term retrospective study.
    Merola A; Espay AJ; Romagnolo A; Bernardini A; Rizzi L; Rosso M; Espay KJ; Zibetti M; Lanotte M; Lopiano L
    Parkinsonism Relat Disord; 2016 Aug; 29():104-8. PubMed ID: 27215392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?
    Merola A; Rizzi L; Zibetti M; Artusi CA; Montanaro E; Angrisano S; Lanotte M; Rizzone MG; Lopiano L
    J Neurol Neurosurg Psychiatry; 2014 May; 85(5):552-9. PubMed ID: 23847290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.
    Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L
    J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
    Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
    Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
    Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
    Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
    Fernández-Rodríguez B; Dupouy J; Harroch E; Fabre-Delcros MH; Barthélémy C; Loubière P; Barange K; Brefel-Courbon C; Rascol O; Ory-Magne F
    Rev Neurol (Paris); 2021 Oct; 177(8):919-923. PubMed ID: 34154827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
    Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
    J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson's disease.
    Lezcano E; Gómez-Esteban JC; Tijero B; Bilbao G; Lambarri I; Rodriguez O; Villoria R; Dolado A; Berganzo K; Molano A; de Gopegui ER; Pomposo I; Gabilondo I; Zarranz JJ
    J Neurol; 2016 May; 263(5):895-905. PubMed ID: 26964542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
    Valldeoriola F; Grandas F; Santos-García D; Regidor I; Catalán MJ; Arbelo JM; Puente V; Mir P; Parra JC
    Neurodegener Dis Manag; 2016 Aug; 6(4):289-98. PubMed ID: 27440190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Freire-Alvarez E; Kurča E; Lopez Manzanares L; Pekkonen E; Spanaki C; Vanni P; Liu Y; Sánchez-Soliño O; Barbato LM
    Mov Disord; 2021 Nov; 36(11):2615-2623. PubMed ID: 34236101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study.
    Tsai ST; Hung HY; Hsieh TC; Lin SH; Lin SZ; Chen SY
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2082-7. PubMed ID: 23916724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
    Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
    Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of subthalamic nucleus deep brain stimulation for Parkinson's disease in Singapore.
    Cai YZ; Zheng Y; Li W; Saffari SE; Ng HL; Zhan A; Xu Z; Tay KY; Au WL; Ng WH; Tan LCS; Wan KR; Neo S
    Ann Acad Med Singap; 2024 Aug; 53(8):481-489. PubMed ID: 39230316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A
    Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.